Relmada Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RLMD research report →
Companywww.relmada.com
Relmada Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults.
- CEO
- Sergio Traversa
- IPO
- 2014
- Employees
- 17
- HQ
- Coral Gables, FL, US
Price Chart
Valuation
- Market Cap
- $525.80M
- P/E
- -10.55
- P/S
- 0.00
- P/B
- 2.84
- EV/EBITDA
- -8.55
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -71.22%
- ROIC
- -27.12%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-57,385,163 · 28.25%
- EPS
- $-1.45 · 45.28%
- Op Income
- $-59,100,200
- FCF YoY
- 11.53%
Performance & Tape
- 52W High
- $8.00
- 52W Low
- $0.49
- 50D MA
- $6.94
- 200D MA
- $3.98
- Beta
- 0.43
- Avg Volume
- 1.89M
Get TickerSpark's AI analysis on RLMD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 15, 25 | TRAVERSA SERGIO | buy | 27,500 |
| Dec 12, 25 | TRAVERSA SERGIO | other | 1,198,000 |
| Dec 12, 25 | Shenouda Maged | other | 828,000 |
| Dec 15, 25 | Shenouda Maged | buy | 11,665 |
| Dec 12, 25 | Ence Chuck | other | 828,000 |
| Dec 12, 25 | Fedeli Fabiana | other | 164,000 |
| Dec 12, 25 | GLASSPOOL JOHN | other | 164,000 |
| Dec 12, 25 | Kelly Paul Edward | other | 828,000 |
| Dec 12, 25 | CASAMENTO CHARLES J | other | 164,000 |
| Nov 5, 25 | Shenouda Maged | buy | 500,000 |
Our RLMD Coverage
We haven't published any research on RLMD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RLMD Report →